209 results about "Guanosine" patented technology

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention discloses a symmetric nucleoside microneedle patch loaded with polymer vesicles as well as a preparation method and application of the symmetric nucleoside microneedle patch. The symmetric nucleoside microneedle patch loaded with the polymer vesicles comprises a guanosine-quadruplex hydrogel microneedle tip doped with drug-loading polymer vesicles, the raw material of the drug-loaded polymer vesicle comprises a polycaprolactone-polyglutamic acid copolymer; the guanosine-quadruplex hydrogel is prepared from the following raw materials: guanosine and KB (OH) 4. The microneedle patch is constructed on the basis of dynamic covalent bond and non-covalent interaction, has a sharp tip array capable of penetrating the epithelium and the lower layer of a mucous membrane, can efficiently deliver a drug to a canker lesion part by bypassing a mucous membrane barrier, can be controllably broken under a high ROS condition of an inflammation microenvironment, has the characteristics of high drug delivery efficiency and high accuracy, and can be used for preparing a medicine for treating the canker lesion part. The effect of effectively improving chemotherapy-induced oral ulceration can be achieved by reducing inflammatory response, relieving pain feeling and inhibiting pain sensitization.

The invention discloses a high-flame-retardant bio-based aerogel material and a preparation method thereof, and belongs to the technical field of flame-retardant bio-based aerogel. The high-flame-retardant bio-based aerogel material prepared by the preparation method disclosed by the invention is prepared from the following raw material components in parts by mass: 10 parts of a bio-based flame-retardant filler with a porous structure, 40 to 50 parts of a hydrophobic siloxane monomer, 12.4 to 12.6 parts of an ammonium phytate solution, 6.2 to 6.3 parts of guanosine, 31.1 to 31.4 parts of cellulose nanofibers and 0.01 to 0.02 part of benzaldehyde-polyethylene glycol-silane, the preparation method comprises the following steps: firstly, carrying out hydrolytic polycondensation on a bio-based flame-retardant filler with a porous structure and a hydrophobic siloxane monomer to form a siloxane polymer network with the bio-based flame-retardant filler as a branching center; then adding cellulose nanofibers, guanosine and an ammonium phytate solution, and performing freeze casting-freeze drying-heating post-treatment to obtain the composite material. Wherein the bio-based flame-retardant filler is obtained by compounding a porous cuttlefish ink carbon quantum dot composite material with phytic acid siloxane and trimethoxy (3-(4-nitrophenoxy) propyl) silane.

The present invention relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases wherein sGC stimulation is increased, or the concentration of nitric oxide (NO) or cyclic 3 ', 5'-guanosine monophosphate (cGMP), or both, is increased, or both, or both. Or an up-regulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are compounds of Formula I or pharmaceutically acceptable salts thereof.

The purpose of the present invention is to provide a novel beer-flavored fermented beverage in which the purine concentration is reduced and the deterioration in flavor due to the reduction in purine concentration is improved. The present invention provides a beer-flavored fermented beverage having a purine concentration of 35,000 ppb or less, an adenosine concentration of 15,000 ppb or less, or a guanosine concentration of 56,000 ppb or less, wherein the 5-methylfurfural concentration is 10 ppb or more.

The invention discloses lactobacillus mucilaginosus and application thereof, and belongs to the technical field of microbial fermentation. The invention provides a lactobacillus mucus WX20 which is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024, and the preservation number of the lactobacillus mucus WX20 is GDMCC No: 65083. The lactobacillus mucus WX20 has the advantages that the lactobacillus mucus WX20 is preserved in the Guangdong Microbial Culture Collection Center on September 12, 2024; the strain obtained by screening can effectively degrade inosine and guanosine and inhibit the activity of xanthine oxidase, and has good tolerance in a simulated gastrointestinal fluid environment. When the strain is used for fermenting the leaf mustard, the fermentation period of the fermented leaf mustard can be shortened, a product prepared by utilizing the strain has the activity of degrading inosine and guanosine and inhibiting xanthine oxidase, a microbial inoculum and pickles can remarkably reduce the blood uric acid level of a mouse with hyperuricemia, and the strain has considerable application potential and high market value.

The present disclosure relates to methods for increasing cell-mediated immunity against varicella zoster virus (VZV) in a human subject in need thereof by administration of an immunogenic composition comprising effective amounts of a VZV glycoprotein E antigen and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for prevention of herpes zoster and / or postherpetic neuralgia.

The present invention relates to certain compounds that function as inhibitors of enzymes which binds guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP) or 5' guanosine triphosphate (GTP) capped RNA, such as enzymes which comprise a RNA cap Guanine N-7 methyl transferase. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of viral infections, as well as other diseases or conditions in which activity of such enzymes is implicated. (Formula (I)

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their use, alone or in combination with one or more additional agents, for the treatment of various diseases wherein the concentration of nitric oxide (NO) and / or the concentration of cyclic guanosine monophosphate (cGMP), or both, is increased, such as, for example, the concentration of nitric oxide (NO) and / or the concentration of cyclic guanosine monophosphate (cGMP). Or regulation of the NO pathway is desirable. In some embodiments, the compound is a compound of Formula I or a pharmaceutically acceptable salt thereof. # imgabs0 #

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention discloses supramolecular hydrogel and microneedle patch for treating oral mucositis and a preparation method and application thereof, and belongs to the technical field of biological medicine, and the supramolecular hydrogel for treating oral mucositis comprises the following raw materials: guanosine, a potassium hydroxide solution containing metal ion soluble salt and phenylboronic acid lactone drugs. The raw material of the microneedle patch further comprises a water-soluble backing solution. The supramolecular hydrogel or microneedle patch for treating oral mucositis integrates antibacterial, anti-inflammatory, antioxidant and angiogenesis promoting functions, and has a remarkable effect of promoting healing of chemotherapeutic oral mucosal lesion.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 21) and its phosphoramidate prodrug (FMCAP, 31) have demonstrated potential anti-HBV activity against both adefovir- resistant as well as lamivudine-resistant double (rtL180M / rtM204V) mutant hepatitis B virus (HBV). In addition, in vitro, these molecules have reinstated a significant activity against lamivudine / entecavir triple mutants (L180M+S202G+M204V). This invention is directed to compounds, pharmaceuticals and methods of treating HBV infections, especially including infections caused by resistant and multiple resistant HBV. Pursuant to the present invention, a complete structure-activity relationship (SAR) of 2'-fluoro-6'-methylene-carbocyclic derived nucleos(t)ides has been evaluated and that analysis is presented herein. Pursuant to the present invention, the synthesis and antiviral evaluation of purine and pyrimidine-derived nucleosides have been reported against wild-type and various HBV mutants. Guanosine analog (FMCG, 25) demonstrated an EC50 value of 0.217μM and cytosine analog (FMCC, 41) expressed a potent EC50 value of 0.0025 μM compared to entecavir (EC50 = 0.0029) against wild-type HBV. Additionally, FMCC (41) maintains its antiviral potency against various HBV mutants. Furthermore, chiral pure FMCAP Sp (34) isomer demonstrated an EC50 value of 1.3 nM and was more potent against several HBV mutants than entecavir.

The invention relates to the technical field of dye separation, and discloses a loose nanofiltration membrane and a preparation method and application thereof, the loose nanofiltration membrane comprises a porous support membrane, and a polyesteramide separation layer formed on the porous support membrane through one-step interfacial polymerization of nucleoside monomers and multi-acyl chloride monomers. The nucleoside monomer is one or more than two of adenosine, guanosine and cytidine nucleoside. The nucleoside monomer with a long-chain structure, a branched-chain structure, a rigid twisted structure and a plurality of hydrophilic reaction sites is selected as an interfacial polymerization water-phase monomer, so that the loose nanofiltration membrane is endowed with excellent permeation and separation performance. The membrane has a high rejection rate on dye molecules such as Congo red and methyl blue, also has high water permeability and extremely high dye / inorganic salt separation selectivity, and shows good application potential in the aspects of dye production and purification and dye wastewater recovery.

This invention relates to a potassium ion-responsive hydrogel based on iminoboronic ester bonds, its preparation method, and its applications. The hydrogel is prepared using guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine. The diol of guanosine forms a borate ester bond with 2-formylphenylboronic acid, and the primary amine in the polyoxyethylenediamine forms an imino group with the aldehyde group of 2-formylphenylboronic acid. The bases of guanosine form a G-quadruplex under the influence of potassium ions. The hydrogel has a porous network structure. The preparation method is as follows: A mixed aqueous solution of guanosine, 2-formylphenylboronic acid, and polyoxyethylenediamine is heated to boiling to obtain a clear solution. After cooling, the solution is mixed with a potassium ion solution to prepare the potassium ion-responsive hydrogel based on iminoboronic ester bonds. Compared with the prior art, the hydrogel prepared by this invention exhibits both temperature and potassium ion responsive characteristics.

The present disclosure relates generally to (CRISPR) RNA (crRNA) for the precision silencing of transcripts. In some embodiments, the crRNA are enriched for guanosine (G) nucleotides at key spacer positions, which is useful in enhancing the silencing efficacy of otherwise inefficient crRNA, thereby expanding the targeting spectrum of Cas13 endonucleases, e.g., Cas13b and Cas13d. In other embodiments, the crRNA comprise a spacer sequence having at least one nucleotide mismatch relative to the target RNA sequence, wherein the target RNA sequence is a wild-type transcript and / or a variant transcript (e.g., a transcript comprising a single nucleotide variant (SNV)). The present disclosure also provides RNA editing systems comprising the crRNA described herein in complex a Cas13 effector protein and a target RNA sequence, methods for the selective targeting of transcripts encoding proteins that are difficult to target, or are not amenable to pharmacological targeting, e.g., oncogenic fusion transcripts or oncogenic transcripts comprising single nucleotide variant(s), and methods for the design and selection of potent crRNA.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The invention relates to a novel modified trinucleotide capped derivative and mRNA introduced with the capped derivative, a methylene bridged heterocyclic compound and a derivative of aryl methyl are respectively introduced at the N7 position of 5 '-terminal guanosine base, and the efficiency is superior to that of a capped substance used in an existing mRNA vaccine; therefore, the present invention can be effectively used in the fields of development of mRNA vaccines and development of various mRNA-based therapeutic agents.

The invention relates to synthesis and application of an N-acetyl protected guanosine RNA monomer, and belongs to the technical field of chemical synthesis. In the prior art for synthesizing RNA, RNA is cut off from a carrier through ammonolysis, the time for synchronously removing an i-Bu protecting group is long, the required reaction temperature is high, RNA degradation, crude product purity reduction, purification difficulty and yield reduction are caused, and long-time ammonolysis causes breakage of fluorescent groups and temperature-sensitive modification groups in an RNA chain structure, so that the RNA is difficult to purify. In addition, the price of isobutyryl chloride or isobutyric anhydride is still high from the perspective of large-scale production, and isobutyric acid generated by removing i-Bu has certain toxicity and is poor in environmental friendliness. Therefore, the invention aims to develop the N-protected guanosine RNA monomer which is simple, easy to obtain, environment-friendly, good in group compatibility, mild in ammonolysis condition, good in stability and easy to remove, so that the problems are solved, and large-scale synthesis of RNA drugs is promoted.

A method for increasing or improving nitric oxide signals or levels, the method comprising: administering a composition to a subject, the composition comprising: arginine or a pharmaceutically acceptable salt, ester, or derivative thereof; and tetrahydrocurcumin and / or β-aminoisobutyric acid or a pharmaceutically acceptable salt or ester thereof. The method and the composition can be used to increase, improve, or enhance nitric oxide signals or levels, inhibit nitric oxide decomposition, and increase or enhance nitrous acid and / or cyclic guanosine monophosphate levels, and can improve fatigue resistance or enhance muscle strength, maintain or improve cardiovascular health, maintain or improve vascular function and structure, inhibit or mitigate endothelial cell damage, or mitigate insufficient blood flow.

The invention belongs to the technical field of biological medicines, and particularly relates to a multifunctional peptide and application thereof in anti-inflammatory, antibacterial, mucous membrane repair and intestinal secretion promotion. Specifically, the invention designs a polypeptide and an analogue which have guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucous membrane repair functions at the same time. The polypeptide can be combined with GUCY2C, stimulate generation of cyclic guanosine monophosphate (cGMP) in cells, promote intestinal fluid secretion, inhibit release of proinflammatory factors, relieve inflammatory response, promote repair of intestinal injury mucosa, inhibit growth of opportunistic pathogenic bacteria and accelerate intestinal homeostasis recovery after intestinal preparation. The composition can effectively promote intestinal tract cleaning, does not cause intestinal inflammation and mucosal lesion, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

The invention relates to the technical field of bioengineering, in particular to an AimA mutant as well as a construction method and application thereof. It is found for the first time that the activity of glutamic acid / serine transporter is weakened, and the nucleoside production capacity of microorganisms can be improved. Based on this, the present invention provides a modified microorganism in which the glutamic acid / serine transporter activity is reduced or lost as compared to an unmodified microorganism, and the nucleoside production capacity of the modified microorganism is enhanced as compared to the unmodified microorganism, and more specifically, the modified microorganism has a reduced or lost glutamic acid / serine transporter activity as compared to the unmodified microorganism. The modified bacillus subtilis or bacillus amyloliquefaciens provided by the invention can generate guanine nucleoside or hypoxanthine nucleoside with high efficiency and high speed.

This invention relates to the field of traditional Chinese medicine detection technology, specifically providing characteristic chromatograms of germinated rice or roasted germinated rice and their preparations, and their construction methods. Using octadecylsilane-bonded silica gel as the packing material, the mobile phase includes methanol and formic acid aqueous solution, gradient elution, and a specific elution program obtained through extensive experimental screening, yielding more than 13 common characteristic peaks. Effective separation of characteristic peaks including uridine, adenosine, guanosine, 5-hydroxymethylfurfural, 4-coumaric acid, and ferulic acid is achieved, with good peak shape, stable baseline, complete separation of the measured components, and short detection time. This provides a basis for the quality detection and control of germinated rice or roasted germinated rice and their preparations, fully reflecting the integrity and characteristics of germinated rice or roasted germinated rice and their preparations. The method is simple to operate and applicable to the quality control of different types of germinated rice or roasted germinated rice preparations.

An oligonucleotide molecule has 10 to 50 nucleotides that include at least one G-quartet forming motif having 10 to 20 nucleotide residues. At least 60% of the residues of the G-quartet forming motif are guanosine or deoxyguanosine residues. The oligonucleotide molecule inhibits tumor growth and / or viral or bacterial replication and / or exerts anti-inflammatory effects in mammalian cells.

The invention discloses a preparation method and application of fucose and an intermediate thereof. The method for synthesizing the GDP-fucose comprises the following steps: taking guanosine diphosphate and cane sugar as substrates, and carrying out catalytic reaction on cane sugar synthase, CDP-tetrose 2-epimerase, GDP-mannose dehydratase and isoreductase to generate the GDP-fucose. The method for synthesizing the fucosyllactose comprises the following steps: taking GDP-fucose and pNP-lactose as initial substrates, and obtaining the fucosyllactose under the catalytic action of Hp13FucT2 enzyme. According to the method for preparing the L-fucose through the enzyme method, fucosyllactose is used as a substrate, and the L-fucose is generated through a fucosidase catalytic reaction. The adopted large intestine expression system has the characteristics of high expression efficiency, large expression quantity, low cost, easiness in operation and the like, and the expressed fucosidase has the advantages of high purity, high yield and the like.

The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

The present application relates to the cosmetic technical field, specifically to a composition containing guanosine component and capable of promoting scalp epidermal cell regeneration and a preparation method, which comprises the following raw material components in percentage by weight: 0.5-20% of surfactant AES, 0.5-10% of biota extract, 0.5-12% of pueraria extract, 0.5-12% of ginger extract, 0.5-10% of ginsenoside extract, 0.5-10% of hydrolyzed corn starch, 0.2-2% of tetraphosphoric acid di-guanosine (GP4G), 1-10% of base liquid, 1-5% of humectant, 0.1-2% of thickening agent, 0.01-1.0% of preservative, and the rest is deionized water. The formula has no irritation, is mild, can significantly increase hair growth and hair volume, increase hair follicle hair retention, inhibit hair loss, promote the re-development of hair follicles, has very significant dandruff and itching relieving functions, and has a simple operation process, and is suitable for industrial manufacturing.

This invention relates to the fields of environmental chemistry and biological sample analysis, specifically to an analytical method for detecting oxidative stress biomarkers in urine. Based on liquid chromatography-tandem mass spectrometry (LC-MS / MS), this invention provides an analytical method for the simultaneous detection of dityrosine, 8-hydroxyguanosine, 8-hydroxydeoxyguanosine, and 4-hydroxynonenal mercaptouric acid in human urine. This method achieves effective purification of urine samples through specific pretreatment, reducing matrix effects, and, combined with specific LC parameters, enables the simultaneous detection of four oxidative stress biomarkers. This method exhibits good selectivity, high sensitivity, and fast detection speed, solving the current problem of the inability to simultaneously determine polar and nonpolar components. It includes a more comprehensive and rational list of oxidative stress biomarkers, better reflecting the body's oxidative stress damage.